Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Authors: Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore, Harold I. Salmons Published: 2026 ABSTRACT Arthrofibrosis following total knee arthroplasty (TKA) is a challenging complication that contributes to failure to achieve functional range of motion and results in physical impairment, pain, and revision surgery. Despite increasing recognition of arthrofibrosis as a biological disease process rather than a purely mechanical complication, there is no single document that integrates current evidence on diagnosis, surgical management, and preventive strategies. In June 2025, the Stavros Niarchos Foundation Complex Joint Reconstruction Center at Hospital for Special Surgery convened an international symposium to address arthrofibrosis following TKA. Invited experts in orthopedic surgery, basic science, biomechanics, and outcomes research were organized into 3 panels focused on (1) basic science, diagnosis, and risk stratification; (2) surgical management and postoperative rehabilitation; and (3) prevention strategies and adjunctive therapies. Each panel reviewed the literature, addressed predefined clinical questions, and developed consensus through structured discussion. This summary describes the recommendations from each panel, emphasizing early, multispecialty evaluation, stage-specific intervention, and procedure-specific rehabilitation strategies. Gaps in the evidence and priorities for future research are highlighted. These recommendations aim to standardize care, guide clinical decision-making, and shift the focus from late salvage toward early identification and prevention of arthrofibrosis following TKA.Level of Evidence: Level V: expert opinion. Introduction The number of total knee arthroplasty (TKA) surgeries is expected to continue its increasing trend. In the United States, annual primary TKA volume is expected to be 2.8 to 3.4 million procedures by 2040, with annual growth rates of approximately 5.9% to 6% from 2023 to 2040, according to recent analyses of Medicare and national inpatient data.1,2 International trends mirror this growth, with most developed countries anticipating increases of 30% by 2030 and up to 800% by 2050, depending on demographic and healthcare system factors.3,4 Approximately 75% to 90% of patients report satisfaction after undergoing TKA in contemporary cohorts.5,6 However, 10% to 15% of patients remain dissatisfied at 1 to 5 years postoperatively, influenced by complications, persistent pain, functional limitations, and unmet expectations.7,8 Arthrofibrosis is a major complication that contributes to long-term functional impairment and dissatisfaction, as it leads to persistent stiffness and diminished quality of life. 9 Patients who develop this condition face an increased risk of reoperation or revision surgery, compounding both patient morbidity and healthcare costs. Despite its impact, arthrofibrosis remains poorly standardized as a clinical entity. There is no universally accepted diagnostic definition, no validated risk-stratification framework, and limited consensus on optimal timing or selection of therapeutic interventions. Arthrofibrosis represents a distinct biological disease state rather than a purely mechanical cause of postoperative stiffness.9,10 Non-biologic etiologies such as malalignment or implant-related complications must be differentiated from pathologic fibrotic processes, as they require fundamentally different management strategies. 9 The maladaptive wound-healing response involves complex interactions among myofibroblasts, inflammatory mediators, immune cells, neurovascular signaling, and mechanical stress. While myofibroblasts serve as effector cells involved in excessive extracellular matrix deposition, fibrosis is governed by a multifactorial signaling network rather than a single pathological factor. 10 Surgical management strategies for arthrofibrosis vary widely and are supported by limited high-level evidence.10-12 Manipulation under anesthesia (MUA), arthroscopic or open lysis of adhesions, and revision TKA are frequently employed, yet optimal procedure selection, timing of intervention, implant choice, and postoperative rehabilitation protocols remain debated. Similarly, preventive approaches, including perioperative patient optimization, pharmacologic intervention, and multidisciplinary care pathways, show promise but lack consolidated clinical guidance.9,11 To address these gaps, in June 2025, an international panel of orthopedic surgeons and musculoskeletal researchers was convened by the Stavros Niarchos Foundation Complex Joint Reconstruction Center at Hospital for Special Surgery to establish consensus-based recommendations addressing arthrofibrosis following TKA. The objectives of this symposium were to clarify arthrofibrosis as a distinct biological entity, outline principles of diagnosis and risk stratification, define evidence-informed approaches to surgical management, and evaluate contemporary strategies aimed at prevention and early intervention. This article presents the panel’s consensus across 3 thematic domains, basic science and diagnosis, surgical management, and prevention strategies, as well as priorities for future research. Methods An international consensus symposium on arthrofibrosis following TKA was convened. An organizing committee of fellowship-trained arthroplasty surgeons, musculoskeletal researchers, and clinician-scientists developed the symposium structure, defined the major thematic domains, selected expert participants, and coordinated the consensus process. Experts were selected based on clinical and/or academic expertise in revision TKA, postoperative stiffness, fibrosis biology, biomechanics, imaging, rehabilitation, or outcomes research. Participants were invited to provide multidisciplinary perspectives and were organized into 3 working groups: (1) basic science, diagnosis, and risk stratification; (2) surgical management and postoperative rehabilitation; and (3) prevention strategies and adjunctive therapies. Each working group performed a literature review relevant to its assigned domain using PubMed/MEDLINE from database inception through March 2025, supplemented by reference-list review and expert-identified publications. Search terms and strategies were structured around predefined clinical and scientific questions assigned to each group (Supplemental Table 1). Eligible literature included English-language clinical studies involving adult TKA populations and translational or basic science studies relevant to fibrosis mechanisms, biomarkers, prevention, or treatment. Studies were excluded if they were not relevant to arthrofibrosis or postoperative stiffness after TKA, did not address one of the symposium domains, or were not available in English. Literature selection and interpretation were performed within each working group, with disagreements resolved by group discussion. Evidence was synthesized thematically to support structured symposium discussion and development of consensus recommendations. When agreement could not be reached, or evidence was insufficient, the topic was identified as an area of uncertainty or a priority for future research. Consensus was defined as endorsement by at least 80% of participating panel members within each working group following structured discussion. Proposed statements were discussed and revised iteratively until the panel either reached this threshold or determined that available evidence was insufficient to support a consensus recommendation. Statements meeting this threshold were included as consensus recommendations. Topics that did not reach consensus were identified as areas of uncertainty and priorities for future research. The consensus process emphasized recommendations while acknowledging limitations in the current evidence. Artificial Intelligence Use Disclosure: The artificial intelligence (AI) tool ChatGPT (OpenAI) was used for editing the text, with all content reviewed and approved by the authors, who take responsibility for the published article. Panel 1: Basic Science and Diagnostic Criteria for Arthrofibrosis Following TKA What Criteria Do We Have for the Diagnosis of Arthrofibrosis of the Knee and Is It Sufficient? Current diagnostic criteria are insufficient and require standardization. The symposium group proposed that there should be new diagnostic criteria that incorporate new biologic understanding of arthrofibrosis. The clinical criteria required for the diagnosis include range of motion (ROM) less than 90° flexion or flexion contracture greater than 10° persisting 3 months postoperatively, 9 magnetic resonance imaging with diffuse synovial thickening, increased expression of associated biomarkers such as transforming growth factor-beta (TGF-β), cartilage oligomeric matrix protein, and tryptase,10,12,13 and histopathology showing myofibroblast proliferation and excessive extracellular matrix deposition. 14 The consensus group emphasized that there is no single clinical presentation that incorporates all of the above findings. An scoring system incorporating these domains could improve diagnostic accuracy, enable earlier identification, and facilitate research standardization. Current diagnostic criteria are inadequate because they rely primarily on clinical examination performed following progression to late-stage disease when therapeutic interventions may be less effective.9,14 Further research is needed to implement and characterize the accuracy of such a scoring system. How Do We Currently Identify Patients at Risk of Arthrofibrosis, and How Should We Adapt Our Risk Classification Going Forward? The group identified risk categories including patient factors, biological factors, medications, biomarkers (Table 1), and environmental factors encompassing social determinants of health. Partial consensus exists on demographic and metabolic risk factors, with diabetes mellitus (DM) showing a stronger association than demographic variables. 15 Other hormonal factors require further investigation. Current early identification remains challenging, requiring recognition of normal post-TKA healing parameters to differentiate pathological from physiological responses. 9 A multidisciplinary approach incorporating longitudinal imaging, kinematic assessment, and biological sampling across multiple time points could enable earlier detection of patients deviating from normal healing trajectories. Table 1.Risk Categories for Arthrofibrosis Following Total Knee Arthroplasty.Risk categorySpecific factorsPatient factorsDemographics, psychological factors, expectations, preoperative ROM, activity level 128 Biological factorsBleeding diathesis, DM, fibrotic/autoimmune diseases, subclinical infection, microbiome10,78,95MedicationsAnticoagulants, DMARDs, chronic NSAIDs11,129,130BiomarkersElevated TGF-β, GPR17, SHH signaling, Notch pathway, ADIPOR1/2, BRD4-mediated modifications10,71,73,101Abbreviations: ADIPOR, adiponectin receptor; BRD4, bromodomain-containing protein 4; DM, diabetes mellitus; DMARDs, disease-modifying antirheumatic drugs; GPR17, G protein-coupled receptor 17; NSAIDs, non-steroidal anti-inflammatory drugs; ROM, range of motion; SHH, sonic hedgehog; TGF-β, transforming growth factor-beta. Risk Categories for Arthrofibrosis Following Total Knee Arthroplasty. Abbreviations: ADIPOR, adiponectin receptor; BRD4, bromodomain-containing protein 4; DM, diabetes mellitus; DMARDs, disease-modifying antirheumatic drugs; GPR17, G protein-coupled receptor 17; NSAIDs, non-steroidal anti-inflammatory drugs; ROM, range of motion; SHH, sonic hedgehog; TGF-β, transforming growth factor-beta. Is There a Single Pathologic Cell Type That Drives Arthrofibrosis? There is no evidence that a single cell type is implicated in arthrofibrosis. The myofibroblast represents an effector cell responsible for excessive collagen production and tissue contraction. Myofibroblast progenitor cells are derived from periosteum and microvasculature. These progenitors demonstrate capacity for rapid proliferation following trauma or surgical injury.14,16 Myofibroblasts appear to operate within a complex signaling network involving bidirectional communication with macrophages, vascular endothelial cells, mast cells, neuropeptides, adaptive immune cells (T cells and B cells), and the extracellular matrix.14,16,17 How Should Management Strategies Differ Between Treatment and Prevention of Arthrofibrosis? Prevention should focus on preoperative identification of high-risk patients using emerging risk stratification tools,18,19 optimized surgical technique minimizing soft-tissue trauma, individualized rehabilitation protocols, and potentially prophylactic biologics in extremely high-risk patients (requires validation). Treatment approaches include early intervention with MUA, 20 progressive surgical interventions for refractory cases, and adjunctive pharmacologic therapies targeting specific pathways.10,17 The panel acknowledged that current interventions have the potential to suppress dysregulated signaling rather than actively reversing established fibrosis.17,21 Surgical debridement removes fibrotic tissue mechanically but does not prevent recurrence if underlying biological factors persist. 20 Emerging pharmacologic therapies targeting TGF-β, mast cells, or other implicated pathways aim to restore homeostatic signaling balance.10,17 True antifibrotic agents that degrade established collagen and reverse myofibroblast phenotype remain investigational, representing a gap in the therapeutic armamentarium. 21 Panel 2: Surgical Management of Arthrofibrosis Following TKA Classification and Evaluation: Consensus on Key Questions The group proposed a classification system applicable to patients with normal preoperative ROM who develop unexpected stiffness following TKA. Evaluation should include clinical assessment and standardized imaging to exclude mechanical failure, malalignment, infection, or implant-related complications. The group proposed development of an algorithm to guide stepwise assessment of patients with postoperative stiffness, integrating time from index arthroplasty, severity of motion loss, and associated clinical factors. Should Arthroscopic Lysis of Adhesions Be Paired Routinely With MUA? No, arthroscopic lysis of adhesions (ALOA) should not be performed routinely. MUA is recommended between 6 weeks and 3 months postoperatively, with earlier intervention associated with better outcomes. ALOA may be considered in combination with MUA beyond 3 months if stiffness persists. MUA is generally considered the first-line intervention for early postoperative stiffness, especially when performed between 6 and 12 weeks of the index surgery, and yields clinically significant improvements in ROM and functional outcomes for most patients.20,22,23 ALOA should be considered in cases where MUA fails and after 3 months from index surgery, in patients with severe, persistent stiffness, particularly when pre-manipulation ROM is extremely limited, as some studies show benefit in this subgroup. 24 The combination of ALOA with MUA does not consistently result in superior outcomes and is associated with higher complication rates, such as surgical site infection and increased rates of revision surgery. 25 Is It Safe to Manipulate an Uncemented Knee? Yes. Although data are limited, early evidence suggests that manipulation of uncemented primary TKA appears safe. Long-term outcomes require further study. One multicenter study and 1 registry study show that the incidence of MUA after cementless TKA is equivalent to that after cemented TKA (3.4% in both groups), and perioperative complication rates—including implant loosening do not occur with greater frequency when compared to cemented implants.26,27 Among patients who underwent MUA, the 5-year revision rates were similar between cemented and cementless groups (7.5% vs 7.1%). There is no evidence that MUA performed within 3 months from index surgery impacts the osseointegration of a cementless TKA. However, more studies are required. Is There a Role for Isolated Open Debridement? A limited role exists. Isolated open debridement may be considered in rare, late-presenting stiff knees with new-onset stiffness or cases where MUA and ALOA have failed, or when there is extensive fibrosis not amenable to arthroscopic techniques. Isolated open debridement (open surgical release) is not considered a routine or first-line treatment for stiffness following TKA, including in cases with severe pre-manipulation knee stiffness. What Is the Best Implant for a Knee With Severe Arthrofibrosis? Posterior-stabilized (PS) or constrained revision implants are appropriate if adequate motion can be restored through soft-tissue releases alone and gap management. In cases of severe motion restriction, extension deficit, or exposure challenges requiring collateral ligament release and/or flexion gap rebalancing, a hinged implant is recommended. In cases of moderate stiffness, where ROM can be restored with soft-tissue releases while preserving the collateral ligaments, a PS implant or a constrained condylar knee (CCK) is an appropriate choice. These designs provide adequate stability in the setting of stiffness without excessive constraint and a lower risk of aseptic loosening. 28 The consensus is that the use of these designs should be prioritized for young, active patients with a long life expectancy, in whom the stiffness was due to malpositioning of the components or inappropriately balanced gaps. Several studies have shown that rotating hinge (RH) prostheses provide significantly greater improvements in ROM compared to non-hinged or less constrained implants in patients with severe arthrofibrosis. For example, patients with preoperative ROM <70° (severe) who underwent revision with an RH implant achieved greater absolute arc of motion gains than those revised with non-RH constructs, with similar functional outcomes at follow-up.29-31 Registry and cohort data indicate 10-year survivorship free from aseptic loosening in 92% for RH and 93% for CCK in complex primary and revision settings. 28 No statistically significant differences have been reported, but a trend toward higher loosening in RH, particularly in younger males, is noted. As a result, experts suggest a more cautious approach that favors the use of PS/CCK designs. What Is the Best Postoperative Recovery Protocol After Intervention for Arthrofibrosis? It depends on the procedure: Post-MUA: early motion is strongly encouraged with continuing targeted physical therapy. Post-MUA: early motion is strongly encouraged with continuing targeted physical therapy. Post-Revision TKA: immobilization for 2 weeks should be considered. Non-aggressive physical therapy should be started after 2 weeks, with a lower threshold for MUA post-revision if progress is stalled. Post-Revision TKA: immobilization for 2 weeks should be considered. Non-aggressive physical therapy should be started after 2 weeks, with a lower threshold for MUA post-revision if progress is stalled. The MUA procedure is followed by immediate and aggressive continuous passive motion and physical therapy. These measures should begin as soon as possible to preserve the ROM gained during the MUA. A randomized clinical trial has shown no benefits of intravenous administration of dexamethasone and oral celecoxib in improving ROM or outcomes. 23 However, most of the panel’s experts prefer to administer anti-inflammatory drugs and need more evidence to change their clinical practice. Complications, such as fractures or wound issues, must be monitored closely. Late MUA is associated with a higher incidence of complications, revision surgery, and repeat MUA. 32 There is no high-level evidence defining the optimal rehabilitation protocol after revision TKA for arthrofibrosis. A direct translation of post-MUA protocols, in the context of revision surgery, can lead to increased inflammation and synovial effusion after a major surgery. It is not uncommon to see a counterproductive early physical therapy program, that is, too aggressive and poses a serious risk to the healing arthrotomy, potentially resulting in wound dehiscence. Expert consensus was strongly in favor of adopting a Quiet Knee protocol. This protocol focuses on controlling inflammation and swelling postoperatively through restricted mobility and passive ROM and aggressive cryotherapy (icing) for the first 10 to 14 days immediately following surgery. During this time window, the arthrotomy and the wound have time to heal without being subjected to mechanical stress. Avoidance of overly aggressive therapy and the use of cryotherapy are supported in the literature. 33 The Quiet Knee protocol remains based on expert consensus. The addition of anti-inflammatory drugs (steroids and non-steroidal anti-inflammatory drugs [NSAIDs]) is strongly recommended. Although there is no published evidence, the experts agreed that the time threshold for MUA following revision surgery should be lowered to 4 weeks. The use of low-dose radiation therapy following revision TKA has been studied in recent years with inconclusive results.34,35 The emerging evidence that low-dose radiation therapy may be a useful adjunct in the management of severe arthrofibrosis and stiffness after revision TKA is promising. 36 Some of the experts shared their unpublished experience with wound dehiscence and subsequent revision for periprosthetic joint infection. In the cohort reported by Schneider et al, no patient experienced these complications. 36 Although this study was conducted rigorously, experts agree that further research is needed to introduce this technique into clinical practice. Does the Use of Robotics Influence the Rates of Postoperative Arthrofibrosis? No. Robotic-assisted TKA does not appear to increase the risk of postoperative stiffness or arthrofibrosis compared with conventional instrumentation, according to experts’ opinion. Several multicenter and registry studies have reported lower rates of MUA after robotic-assisted TKA, suggesting a modest protective effect, likely mediated through improved alignment and gap balancing.37-40 However, other cohorts and meta-analyses have found no significant difference in stiffness-related complications between robotic and manual techniques, indicating that patient-related factors and the healing response remain the dominant determinants of arthrofibrosis.41-45 This conclusion is limited by heterogeneity in robotic systems, study designs, and definitions of stiffness. Further high-quality, long-term studies are needed to clarify whether robotic assistance meaningfully reduces the risk of postoperative stiffness after TKA. Does Leaving the Knee Slightly Looser During Surgery Help Reduce the Risk of Arthrofibrosis or Does It Achieve the Exact Opposite? Current understanding does not support intentionally under-constraining the knee as a strategy to prevent arthrofibrosis. A limited number of studies suggest this strategy to mitigate the risk of arthrofibrosis.46,47 There is ample data showing that excessive laxity will lead to a different set of problems (chronic pain, instability, chronic effusion) and will not protect from arthrofibrosis. What Is the Impact of Avoiding Coronal (Extension Space) Over-Tightness in TKA on Arthrofibrosis Outcomes? Avoiding coronal (extension space) over-tightness during TKA reduces the risk of postoperative arthrofibrosis and flexion contracture. Intraoperative over-tightening of the extension gap increases soft-tissue tension, which is a well-established risk factor for postoperative stiffness and arthrofibrosis. Is It Possible That Alternative Alignment Strategies Could Lead to a Reduction in Rates of Stiffness? There is insufficient data to address this. Alternative alignment strategies such as unrestricted kinematic, restricted kinematic, inverted kinematic, and functional alignment may reduce the need for soft-tissue releases and are associated with similar or slightly improved early patient-reported outcomes and ROM compared to mechanical alignment, but do not show a statistically significant reduction in rates of postoperative stiffness or arthrofibrosis. Kinematic and functional alignment techniques can provide modest improvements given the intrinsic limitation of soft-tissue releases, but these differences are generally small and not consistently clinically significant, with no statistical difference in complication rates, including stiffness, at 1 to 2 years.48-51 Do Surgeons Have Intraoperative Tools to Assess Knee Kinematics Under Anesthesia? No. On the market there is a range of intraoperative tools to assess knee kinematics and soft-tissue balance under anesthesia, but these tools have no role in predicting and preventing postoperative stiffness and arthrofibrosis.52-54 The experts think that the first challenge is determining what is most important to measure. It seems that balance may matter more than alignment. Ultimately, a reliable tool that objectively measures balance in both flexion and extension may be useful. How Strong Is the Evidence on the Effectiveness of Home Stretching Devices? The evidence supporting the effectiveness of home stretching devices in preventing arthrofibrosis after TKA is promising but remains limited in quality and strength. In cases of stalled physical therapy, static stretch devices can yield improvements in knee ROM and high patient satisfaction in patients with refractory stiffness or arthrofibrosis after TKA.55,56 One study showed equal or superior results of stretching devices over MUA. 57 The evidence is encouraging, but high-quality, standardized, long-term studies are still needed to establish best practices and confirm their impact on clinically meaningful outcomes. Panel 3: Prevention Strategies and Pharmacologic Treatment Options for Arthrofibrosis This expert panel consisted of orthopedic surgeons who have performed basic, translational, and/or clinical research around the topic of prevention and treatment of arthrofibrosis after TKA. The experts emphasized the importance of distinguishing “arthrofibrosis” as a biological disease state in which excessive scar tissue is deposited in the knee joint. This contrasts with non-biologic causes of stiffness after TKA such as malalignment, infection, or surgical technique errors. This differentiation was considered crucial by the symposium members, as most contemporary prevention and treatment strategies target the pathophysiologic cascade leading to excessive scar deposition following surgical trauma. The following questions were discussed. How Might AI-Based Predictive Analytics Be Integrated Into Risk Stratification for Arthrofibrosis? The panel concluded that, as of June 2025, AI lacks sufficiently high-fidelity, large-scale databases to generate meaningful predictive models capable of identifying patients at risk for arthrofibrosis after TKA. AI represents an emerging tool in orthopedic surgery, capable of identifying trends and correlations within massive datasets to answer complex clinical questions.58-64 The current role of AI in preoperative planning shows potential, and AI models have demonstrated the ability to analyze large numbers of operative covariates and outcomes such as implant sizes, favorable anatomical alignment, and even postoperative patient dissatisfaction.65-69 Indeed, risk modeling with machine learning has been shown to outperform conventional linear regression methodology in risk modeling across numerous orthopedic domains.58,60,63 Furthermore, AI potentiates the implementation of clinician-ready mobile applications and electronic medical record (EMR) add-ons to aid in the potential detection of complications after joint arthroplasty. In arthrofibrosis following TKA, at-risk patients exhibit exaggerated fibrotic responses to surgical trauma compared to non-arthrofibrotic controls.11,70-73 Recent literature has identified an array of 9 serum cytokines that tend to be elevated in the first 48 hours following TKA in patients who develop stiffness in the first 6 postoperative weeks. 74 These biomarkers could play a role in predicting arthrofibrosis for the patient immediately following TKA. AI algorithms could aid in developing preoperative risk assessment tools to enable earlier intervention and personalized postoperative surveillance. 75 Additional recent literature has demonstrated that AI-enabled wearable devices may be useful in monitoring ROM following TKA.76,77 Interestingly, in another study, a machine-learning model was applied to patients undergoing primary TKA to predict poor ROM between 1 and 6 months postoperatively. 76 They found that the key factors were preoperative elevated hemoglobin A1c levels (of greater than 6.0%), intraoperative joint-line change of 3.0 mm or greater, and postoperative femoral-tibial angle of 174° or less. Other studies have also found that preoperative DM, as well as intraoperative joint line elevation by 4 mm or more, represent risk factors for poor ROM following TKA.78,79 It should be noted that Saiki et al accepted a higher ROM than previously described to define, suggesting the need for caution in interpreting these results.9,20,24,25,76,80 Despite these promising advancements, our consensus panel agreed that current limitations in AI-based models stem from inconsistent and low-fidelity data collection and limited external validity to existing studies. 81 While complete disease pathogenesis has yet to be elucidated in the literature, there are likely numerous variables of importance (such as cytokine profiles/inflammatory markers, oxidative stress markers, and standardized range-of-motion outcomes) that are rarely captured in large registries. Moreover, the lack of a specific diagnostic code for biologic arthrofibrosis (as opposed to surrogate metrics like MUA) hampers accurate disease classification. Indeed, the authors agree that MUA as a surrogate for arthrofibrosis is a common finding in both registry-based and prospective studies. The heterogeneity of indications for MUA suggests the need for more specific disease classification codes for biologic arthrofibrosis. The panel remains hopeful that future research will result in an AI-generated arthrofibrosis risk factor classification system algorithm similar to what has been develop for risk prediction with venous thromboembolism.82,83 Can Preoperative Stratification Models Incorporating Comorbidities, Genetic Risk, and Baseline ROM Guide Individualized Prophylaxis Plans? Preoperative risk-stratification models hold substantial promise for integrating known risk factors into actionable clinical care plans for patients who are developing arthrofibrosis. However, no clear preoperative stratification model to individualize arthrofibrosis prophylaxis following TKA currently exists, and further refinement is required through large-scale data validation. Risk modeling has been a significant focus in contemporary orthopedic literature.84,85 Applying similar frameworks to arthrofibrosis as a complication after TKA should enable preventative measures to be implemented in at-risk populations. Validated preoperative clinical evaluation models are lacking, in spite of many clearly documented patient-related risk factors for arthrofibrosis following TKA in the literature. 86 Risk factors for arthrofibrosis (and potential MUA) post-TKA include younger age at TKA, presence of DM, smoking, history of prior knee surgery/preoperative stiffness, longer tourniquet times, prior hyper-granulation or keloid scarring, psychological factors (depression, pain catastrophizing), low preoperative ROM, and general anesthesia.78,87-94 EMR systems offer a comprehensive means of detecting and recording this granular data that may aid the development of risk-prediction tools. As such, the panel supports the integration of data from the EMR to stratify and map patient-related risk factors as an important area of prospective study. The potential genetic and biological predisposition component was also discussed. While certain pro-fibrotic conditions such as Dupuytren’s disease, Ledderhose disease, Peyronie’s disease, and hyper-granulation or keloid formation have been weakly associated with arthrofibrosis, no single gene, biomarker, or genetic panel has been validated as a definitive predictor.10,95-97 Unfortunately, serum C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels are not indicative of the cytokine surge thought to be associated with arthrofibrosis. 98 The TGF-β1 pathway and associated cytokine cascades appear to mediate fibrotic responses following surgical trauma.74,99,100 An early study of molecular biomarkers for arthrofibrosis as potential targets for risk profiling and pharmacological treatment in patients undergoing TKA has been reported but is far from current practice. 101 At present, preoperative stratification of patients indicated for primary TKA deemed at high-risk for postoperative arthrofibrosis is based solely on identification of clinical risk factors, as well as individual surgeon experience. Ultimately, the panel envisioned a multifactorial model incorporating the following: Biochemical Markers: ESR, CRP, eosinophil, and leukocyte counts. Biochemical Markers: ESR, CRP, eosinophil, and leukocyte counts. Clinical Factors: age, diabetes status, prior fibrotic history (keloid formation, Dupuytren’s disease, Peyronie’s disease, etc), trauma history, low baseline ROM. Clinical Factors: age, diabetes status, prior fibrotic history (keloid formation, Dupuytren’s disease, Peyronie’s disease, etc), trauma history, low baseline ROM. Psychosocial Factors: depression, anxiety, pain catastrophizing, opioid dependency. Psychosocial Factors: depression, anxiety, pain catastrophizing, opioid dependency. These models require extensive validation but could eventually enable personalized treatment plans. Our panel expressed curiosity regarding how oxidative stress might be a factor involved in the development of arthrofibrosis following TKA. This remains an untapped area of study. 99 Can Preoperative Multidisciplinary Care Involving Pain Management, Psychology, Physical Therapy, and Other Consults Help in Preventing Post-Surgical Stiffness? The panel reached unanimous agreement that multidisciplinary care remains underutilized in the prevention of postoperative stiffness and acquired idiopathic arthrofibrosis. Pain control plays a pivotal role both clinically and biologically. Clinically, lower pain scores correlate with improved early ambulation and postoperative ROM; biologically, nociceptive stimuli can activate mast cells and macrophages, initiating pro-fibrotic and pro-inflammatory cascades as demonstrated in numerous basic and translational studies.73,98,102 A recent meta-analysis of level I randomized controlled trials by Tzu-Han et al found that using multidisciplinary complementary interventions (physical therapy combined with cognitive behavioral therapy) resulted in significantly lower reported rates of kinesiophobia, alongside significantly higher rates of functional improvement, up to and beyond 6 months post-primary TKA. 103 Similarly, it is believed that an automated referral pathway to members of the multidisciplinary team at the time of preoperative assessment would inevitably facilitate higher engagement levels with physical therapists, clinical psychologists, and other necessary services, thereby enhancing early detection of arthrofibrosis following TKA. Integration of such a streamlined multidisciplinary team referral pathway into preoperative assessment would be of benefit in arthrofibrosis prevention following TKA. The panel advocated for proactive integration of: Pain psychology and cognitive behavioral therapy for preoperative pain management. Pain psychology and cognitive behavioral therapy for preoperative pain management. Prehabilitation physical therapy to optimize ROM and strength. Prehabilitation physical therapy to optimize ROM and strength. Automated referral systems within the EMR to connect at-risk patients to pain management and mental health services. Automated referral systems within the EMR to connect at-risk patients to pain management and mental health services. Such interventions could reduce administrative burden while enhancing compliance and early identification of high-risk patients for arthrofibrosis. What Is the Optimal Timing for Intervention: Prehabilitation, Intraoperative Measures, or Immediate Postoperative Care—When Aiming to Prevent Fibrotic Complications? Early intervention was endorsed as essential to mitigating postoperative stiffness, with the early postoperative window (2-4 weeks) considered an essential timeframe to intervene on the arthrofibrotic cascade, particularly with examination findings suggestive of arthrofibrosis. Because fibrotic pathways after TKA begin to activate as early as 48 hours after surgery, marking this time point a critical window for initiating interventions to prevent arthrofibrosis. 104 Animal models have demonstrated that myofibroblast activation peaks approximately 2 weeks after surgery, suggesting that antifibrotic interventions may be most effective within this early postoperative window, prior to myofibroblast differentiation and activation.105,106 Conversely, higher revision rates are observed with delayed intervention in arthrofibrotic TKA. 69 Early rehabilitation strategies may not only enhance functional recovery, but also help minimize postoperative pain.68,70 There is a strong correlation between pain and stiffness after TKA, each often contributing to the other and both significantly impacting patient satisfaction and functional outcomes. The goal is to break the vicious cycle of stiffness as a cause of pain and pain as a contributor to stiffness.75,76 Regarding MUA, the most common non-operative means of addressing a stiff TKA postoperatively, clinical evidence supports early (≤6 weeks) MUA over delayed procedures due to reduced scar maturation and better outcomes.23,107 MUAs are not without risks. As such, care must be taken during the procedure to prevent distal femur or tibial periprosthetic fractures or extensor mechanism disruptions. The panel recommended postoperative evaluations every 2 to 3 weeks for high-risk patients. This can be conducted via telehealth to avoid logistical and billing issues that often arise with in-person follow-up visits. Some studies have reported that structured telephone follow-up after TKA significantly increases patient adherence to home exercise programs, leading to better ROM and reduced functional difficulty. 77 In addition, mobile applications and wearable device platforms are increasingly used to monitor and support patients after TKA and show promise in improving outcomes.9,78,79 What Role Could Wearable Motion Sensors Play in Identifying Patients at Risk for Arthrofibrosis Through Early Detection of Abnormal Recovery Patterns? Wearable motion sensors and remote activity trackers offer an innovative avenue for continuous monitoring of functional recovery following TKA that could prove useful for identifying patients at risk of arthrofibrosis. However, current practical barriers to their utility include patient compliance, data integration, and administrative workload for clinical teams. Wearable technology that detects patient’s functional status postoperatively provide massive amounts of data to the treatment team. This includes continuous assessment of ROM recovery, gait parameters, and activity levels.80,81,84,85,108 These devices could facilitate telerehabilitation by allowing clinicians to monitor patients’ progress remotely, specifically in those with kinesiophobia.89,103 While this affords surgeons an opportunity to flag deviations from expected recovery curves indicative of patients at risk of stiffness, further research is needed to fully establish optimal recovery curves and how to interpret these data in terms of setting a normal versus abnormal threshold.86,87 Because limitations outweigh benefits to this wearable technology in detecting patients progressing toward postoperative knee stiffness, the panel recommended ongoing research into automated algorithms that could analyze sensor data in real-time and trigger clinical alerts for abnormal recovery patterns, ideally integrating with EMR systems to support timely interventions. What Risk Factors Should Be Included in a Novel Classification System for Predicting Arthrofibrosis Risk? A comprehensive classification system for arthrofibrosis risk should incorporate clinical, biological, behavioral, and procedural factors, many of which have been identified in recent literature. The panel highlights that certain patient-specific characteristics and perioperative variables are consistently associated with a higher likelihood of postoperative stiffness and thus should be integrated into any predictive model (Table 2). Table 2.Risk Factors for Arthrofibrosis After TKA Demonstrated in the Literature.Risk factors for arthrofibrosisSupporting publicationsPrior MUAKazarian et al 109 Keloid or fibrotic disease historyWang et al 95 and Flick et al 96 Elevated early cytokinesMalahias et al 74 Postop DVTBudin et al 110 Low activity/ROMOwen et al 88 Younger age at surgeryOwen et al 88 and Van de Ven et al 90 Prior surgery or traumaOwen et al 88 Chronic pain, opioid use disorder, depression/anxiety, psychosocial variables-Dupuytren’s, Ledderhose, and Peyronie’s diseasesWang et al 95 Hyperglycemia/diabetes mellitusWada et al 78 Cementless robot assisted TKALee et al 44 Abbreviations: DVT, deep vein thrombosis; MUA, manipulation under anesthesia; ROM, range of motion; TKA, total knee arthroplasty. Risk Factors for Arthrofibrosis After TKA Demonstrated in the Literature. Abbreviations: DVT, deep vein thrombosis; MUA, manipulation under anesthesia; ROM, range of motion; TKA, total knee arthroplasty. The key patient-related factors include: (1) a history of fibrotic conditions, such as keloid, Dupuytren’s disease, Ledderhose disease, or Peyronie’s disease, that may reflect a genetic predisposition to pathological fibrosis 95 ; (2) younger age at surgery, which has been associated with a more reactive postoperative inflammatory profile 87 ; (3) pre-existing hyperglycemia or DM, which is linked to systemic inflammation and impaired tissue remodeling 78 ; (4) psychological factors such as pain catastrophizing that may negatively influence pain perception, rehabilitation engagement, and outcomes 92 ; and (5) the presence of low preoperative activity, or poor ROM, which may both reflect and contribute to developing arthrofibrosis.93,94 Relevant clinical and surgical history includes: (1) prior MUA, which is itself a marker of prior fibrosis 88 and (2) previous surgery or trauma to the affected joint, increasing baseline fibrosis or joint scarring. 109 Emerging biological and perioperative predictors are also critical with (1) elevated early cytokine levels, indicating a pro-fibrotic inflammatory state 10 or (2) postoperative deep vein thrombosis, which may contribute to local inflammation and immobility.88,110 These factors have been discussed above. The panel felt that combination of these diverse yet complementary factors may yield a classification tool to stratify patients pre- and postoperatively who may be predisposed to arthrofibrosis post-TKA, therefore enabling earlier intervention, as well as tailored rehabilitation strategies. Where Are We With Pharmacologic Interventions to Prevent Stiffness? Pharmacologic strategies for preventing post-surgical stiffness remain largely investigational, with limited or weak supporting evidence for most agents currently in use or under study (Table 3). The panel acknowledged that while some interventions show theoretical or anecdotal promise, robust clinical validation is still lacking for the majority of pharmacologic options. Table 3.Review of Previously Studied Medications in the Prevention and Treatment of Arthrofibrosis.Pharmacologic category/interventionSummary of evidenceAnti-inflammatory agentsOverall, limited evidence supports their efficacy in preventing postoperative stiffness NSAIDsLimited evidence for prevention of arthrofibrosis in animal models as well as clinical series11,23,70,72,111,131 CorticosteroidsDemonstrated benefit in postoperative pain control; emerging evidence suggests potential in mitigating fibrotic progression11,132AntihistaminesWeak evidence; limited data supporting antifibrotic benefit72,133-135Antihypertensives (Losartan)Limited clinical evidence111,136Antioxidants (general)Weak evidence; animal data suggest benefit, human data are lacking137,138Postoperative TXALimited evidence; however, Level I RCT demonstrated improved knee flexion and pain scores at 6-week postop with extended p.o. TXA vs control 127 Experimental interventions EGCG (green tea extract)Weak evidence; limited data suggest potential antifibrotic potential 139 “Quiet Knee” protocol (restricted ambulation for first 2 postoperative weeks)No published evidence, anecdotal institutional experience demonstrating reduction in early pain and inflammation after TKA. Area of ongoing exploration Synthetic adiponectin receptor 1 mimetic (AdipoRon)Weak evidence; multiple mammalian studies demonstrating antifibrotic and anti-inflammatory potential, including specifically for knee contracture71,73,99 MetforminThe evidence for metformin in knee arthrofibrosis is moderate in preclinical models but emerging in human trials140,141Abbreviations: EGCG, epigallocatechin gallate; NSAIDs, non-steroidal anti-inflammatory drugs; TKA, total knee arthroplasty; TXA, tranexamic acid, RCT, randomized controlled trial. Review of Previously Studied Medications in the Prevention and Treatment of Arthrofibrosis. Abbreviations: EGCG, epigallocatechin gallate; NSAIDs, non-steroidal anti-inflammatory drugs; TKA, total knee arthroplasty; TXA, tranexamic acid, RCT, randomized controlled trial. Among the most commonly used classes, anti-inflammatory medications are the most prevalent. NSAIDs are widely used postoperatively and may provide some symptomatic relief and lower risk of arthrofibrosis as well as need for MUA. 103 Furthermore, there is clinical evidence that sustained NSAIDs combined with corticosteroids post-TKA are associated with a reduced incidence of acquired idiopathic knee stiffness and MUA.11,111 Selective cyclooxygenase-2 inhibitors (a type of NSAID) also show a protective effect. 53 The expert panel supports sustained dosing of anti-inflammatory agents postoperatively to mitigate pro-fibrotic cascades mediated by TGF-β1 in response to surgical trauma.11,70-72,86,99,105 Despite these promising results, NSAID efficacy in preventing arthrofibrosis is not well-established. 23 Corticosteroids both systemic and intra-articular have a stronger evidence base for pain control, and the panel suggests they may have greater potential for modulating fibrotic pathways, though further study is needed to confirm this effect.103,112 Other pharmacologic agents have been proposed with weak or preliminary evidence: antihistamines, antihypertensives, vitamin C, and antioxidants have all been investigated to varying degrees, but none currently demonstrate convincing clinical impact in reducing fibrosis or improving long-term motion outcomes. Postoperative oral tranexamic acid (TXA) given during postoperative days 1 to 3 has also been explored and compared to conventional TXA administration; patients with extended TXA showed significantly increased knee flexion at 6 weeks, but this use in preventing stiffness should be more explored.44,104 Several experimental or emerging interventions such as epigallocatechin gallate (EGCG), the main active compound in green tea, has been studied for its antifibrotic properties, 113 but there is no direct clinical evidence supporting the use of EGCG for preventing stiffness after TKA. 114 In summary, while the pharmacologic toolbox for preventing arthrofibrosis is expanding, no intervention has yet achieved high-level evidence or broad clinical consensus. Ongoing trials and translational research will be critical to define which agents are most effective and in what context they should be implemented. Discussion There are substantial gaps in the diagnosis and management of post-TKA arthrofibrosis, particularly in the reliance on late clinical findings rather than early biological indicators that could lead to earlier intervention.9,14 Emerging frameworks advocate for a multidimensional diagnostic approach incorporating imaging, biomarkers, and patient-reported outcomes to better characterize fibrotic progression at earlier stages.9,12 However, translation into clinical practice will require validated biomarker panels, standardized imaging protocols, and established recovery trajectories to distinguish pathological fibrosis from expected postoperative inflammation.12,13 Without these benchmarks, opportunities for early, preventive intervention remain limited. Mechanistic advances further demonstrate that arthrofibrosis involves complex interactions between myofibroblasts, immune signaling, mechanical loading, and local tissue environments, explaining the limited success of current single-target therapies.14,17 Systemic administration of biologics results in suboptimal local concentrations and potential systemic toxicity, while surgical interventions remove fibrotic tissue without addressing underlying factors in recurrence. 20 The development of targeted delivery systems, including sustained-release formulations and stimuli-responsive platforms, could dramatically improve therapeutic efficacy. Equally important is the recognition that timing matters critically, with different interventions required at different stages of disease progression. 17 Future research must prioritize understanding the critical transition point from adaptive healing to maladaptive fibrosis, as interventions targeting this switch could prevent arthrofibrosis rather than merely treating established disease. 17 The parallels with fibrosis in other organ systems suggest that knowledge translation from pulmonary, hepatic, and dermal fibrosis research could accelerate therapeutic development, 21 though the unique biomechanical environment of post-TKA knees requires adaptation rather than direct application.14,16 An important theme emerging from the symposium was the recognition of postoperative stiffness as a syndrome rather than a single diagnosis. This reframing underscores the need for a structured evaluation in patients who develop unexpected stiffness despite normal preoperative ROM. Exclusion of infection, malalignment, component malposition, and implant-related factors is critical before implementing motion-restoring interventions, as failure to identify correctable mechanical or biological factors risks ineffective treatment. This phenotype-based approach helps align intervention choice with the dominant etiology of stiffness rather than applying uniform algorithms. Timing emerged as a consistently modifiable determinant of outcome. MUA remains the preferred first-line intervention for early postoperative stiffness, with greater gains in motion observed when performed within the early postoperative window. Beyond the early postoperative period, intervention should be reserved for selected cases. Routine combination of ALOA with MUA is discouraged, as the panel highlights that it does not reliably yield superior outcomes and is associated with higher complication rates, including infection and increased revision risk. Instead, ALOA may be considered for persistent stiffness following failed MUA, particularly in later presentations where intra-articular adhesions are suspected to be the primary cause. Early MUA appears safe in cementless primary TKA, with no evidence suggesting compromise of early fixation. Post-intervention rehabilitation is portrayed as procedure-specific rather than “one protocol fits all.” After MUA, immediate motion and targeted therapy are emphasized to preserve manipulation gains. Conversely, after revision for arthrofibrosis, the group cautions against translating aggressive post-MUA protocols to a major reconstructive procedure, where excessive early therapy may exacerbate inflammation and effusion and jeopardize wound/arthrotomy integrity. The “Quiet Knee” strategy, involving restricted mobility and passive ROM with cryotherapy for the first 10 to 14 days, along with anti-inflammatory pharmacotherapy, is aimed at reducing the biological aspect of recurrent fibrosis. The panel also supports a lower threshold for early post-revision MUA (around 4 weeks) when motion recovery is clearly failing, recognizing the time-sensitive nature of fibrosis maturation. In addition, expectations regarding technologic prevention strategies are tempered. Robotic-assisted TKA does not appear to increase the risk of arthrofibrosis; however, whether it reduces postoperative stiffness remains uncertain, given heterogeneity in systems, definitions, and study designs. Similarly, current evidence does not support intentionally “leaving the knee looser” as a preventive strategy, although avoiding excessive extension-space tightness may reduce stiffness risk without compromising stability. Preventive strategies for arthrofibrosis remain limited by the absence of reliable preoperative risk-prediction tools. While AI has shown promise in orthopedic outcome prediction, its ability to accurately forecast post-TKA arthrofibrosis is currently constrained by heterogeneous datasets and the lack of biologically informative inputs, including inflammatory and cytokine profiles.65-69,74 Similarly, preoperative risk stratification models remain underdeveloped in clinical practice, with most assessments relying on surgeon judgment rather than validated tools. 77 Despite established patient-related risk factors, no genetic or biomarker-based test is available to predict postoperative stiffness, and emerging associations with oxidative stress and early cytokine surges remain investigational.9,10,87-91,94,98,101 A comprehensive, prospective stratification framework integrating clinical, perioperative, psychological, and biological variables represents a critical unmet need in arthrofibrosis prevention.115-119 Early postoperative intervention is emphasized as a cornerstone of prevention. Fibrotic signaling pathways are believed to activate within the first 48 hours following surgery, supporting the importance of immediate mobilization and structured rehabilitation beginning within 24 to 48 hours.106,119-121 Tailored physical therapy protocols, close monitoring during the first 2 to 3 postoperative weeks, and early identification of aberrant recovery trajectories may interrupt progression toward established fibrosis. Adjunctive strategies, including telerehabilitation and remote monitoring, have shown promise in maintaining adherence and enabling early intervention, though implementation barriers persist.122-126 Pharmacologic strategies remain largely adjunctive and investigational. Large registry studies suggest that NSAIDs and corticosteroids are associated with reduced rates of postoperative stiffness and MUA, although their direct antifibrotic effects require prospective validation.111,112,118 Protocols such as postoperative corticosteroid rescue strategies warrant further study, while other agents, including antioxidants, antihistamines, and extended TXA regimens, currently lack sufficient evidence to support routine use. 127 Collectively, prevention and treatment of arthrofibrosis will likely depend on a multimodal approach combining early rehabilitation, targeted pharmacologic adjuncts, and future biologically informed risk stratification tools. Future Directions Progress in post-TKA arthrofibrosis should focus on identifying abnormal healing earlier and intervening before fibrosis becomes established. Research priorities include defining simple early markers of risk, such as short-term inflammatory signals and early postoperative motion patterns, and establishing clear benchmarks for normal versus pathological recovery. Treatment strategies should be stage-specific, recognizing that early inflammatory stiffness and late fibrotic disease require different approaches. Development of locally targeted therapies and standardized, prospective datasets will be essential to support practical risk-stratification tools and shift care from late salvage toward prevention. In conclusion, arthrofibrosis following TKA is a complex, biologic condition that remains underdiagnosed, variably treated, and insufficiently prevented in current clinical practice. This consensus document highlights the need to move beyond late, purely clinical definitions toward earlier, multidimensional assessment that integrates biological, mechanical, and patient-specific factors. Timely, selective intervention—particularly early MUA—with procedure-specific rehabilitation strategies are critical to optimizing outcomes. Preventive efforts should prioritize early postoperative monitoring, individualized rehabilitation, and adjunctive pharmacologic therapies. Progress will depend on standardized definitions, prospective data collection, and risk-stratification frameworks that enable prevention rather than late salvage. Supplemental Material sj-docx-1-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-1-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-2-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-2-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-3-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-3-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-4-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-4-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-5-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-5-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-6-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-6-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-7-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-7-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-8-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-8-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-9-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-9-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-10-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-10-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-11-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-11-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-12-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-12-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-13-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-13-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-14-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-14-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-15-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-15-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-16-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-16-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-17-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-17-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-18-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-18-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-19-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-19-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-20-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-20-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-21-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-21-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-22-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-22-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-23-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-23-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-24-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-24-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-25-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-25-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal® sj-docx-26-hss-10.1177_15563316261474517 – Supplemental material for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium Supplemental material, sj-docx-26-hss-10.1177_15563316261474517 for Arthrofibrosis After Total Knee Arthroplasty: Biological Mechanisms, Diagnosis, and Treatment: An International Consensus Symposium by Peter K. Sculco, Ronald E. Delanois, Gwo-Chin Lee, William A. Jiranek, Matthew P. Abdel, Laura Moore and Harold I. Salmons in HSS Journal®